Ombitasvir; Paritaprevir; Ritonavir Patent Expiration

Ombitasvir; Paritaprevir; Ritonavir is Used for treating Hepatitis C virus (HCV) infection. It was first introduced by Abbvie Inc in its drug Technivie on Jul 24, 2015.


Ombitasvir; Paritaprevir; Ritonavir Patents

Given below is the list of patents protecting Ombitasvir; Paritaprevir; Ritonavir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Technivie US8691938 Anti-viral compounds Apr 13, 2032 Abbvie
Technivie US8420596

(Pediatric)

Macrocyclic hepatitis C serine protease inhibitors Oct 10, 2031 Abbvie
Technivie US8686026 Solid compositions Jun 09, 2031 Abbvie
Technivie US8420596 Macrocyclic hepatitis C serine protease inhibitors Apr 10, 2031 Abbvie
Technivie US9044480 Compositions and methods for treating HCV Apr 10, 2031 Abbvie
Technivie US9006387 Anti-viral compounds Jun 10, 2030 Abbvie
Technivie US8642538 Macrocyclic hepatitis C serine protease inhibitors Sep 10, 2029 Abbvie
Technivie US8268349

(Pediatric)

Solid pharmaceutical dosage form Feb 25, 2025 Abbvie
Technivie US8399015

(Pediatric)

Solid pharmaceutical dosage form Feb 25, 2025 Abbvie
Technivie US8268349 Solid pharmaceutical dosage form Aug 25, 2024

(Expired)

Abbvie
Technivie US8399015 Solid pharmaceutical dosage form Aug 25, 2024

(Expired)

Abbvie
Technivie US7364752

(Pediatric)

Solid dispersion pharamaceutical formulations May 10, 2021

(Expired)

Abbvie
Technivie US7364752 Solid dispersion pharamaceutical formulations Nov 10, 2020

(Expired)

Abbvie
Technivie US7148359

(Pediatric)

Polymorph of a pharmaceutical Jan 19, 2020

(Expired)

Abbvie
Technivie US7148359 Polymorph of a pharmaceutical Jul 19, 2019

(Expired)

Abbvie
Technivie US6037157

(Pediatric)

Method for improving pharmacokinetics Dec 26, 2016

(Expired)

Abbvie
Technivie US6703403

(Pediatric)

Method for improving pharmacokinetics Dec 26, 2016

(Expired)

Abbvie
Technivie US6037157 Method for improving pharmacokinetics Jun 26, 2016

(Expired)

Abbvie
Technivie US6703403 Method for improving pharmacokinetics Jun 26, 2016

(Expired)

Abbvie



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ombitasvir; Paritaprevir; Ritonavir's patents.

Given below is the list recent legal activities going on the following patents of Ombitasvir; Paritaprevir; Ritonavir.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 09 Nov, 2022 US9044480
Payment of Maintenance Fee, 8th Year, Large Entity 14 Sep, 2022 US9006387
Payment of Maintenance Fee, 8th Year, Large Entity 09 Sep, 2021 US8691938
Payment of Maintenance Fee, 8th Year, Large Entity 09 Sep, 2021 US8686026
Payment of Maintenance Fee, 8th Year, Large Entity 15 Jul, 2021 US8642538
Payment of Maintenance Fee, 8th Year, Large Entity 15 Sep, 2020 US8420596
Payment of Maintenance Fee, 4th Year, Large Entity 15 Nov, 2018 US9044480
Payment of Maintenance Fee, 4th Year, Large Entity 13 Sep, 2018 US9006387
Payment of Maintenance Fee, 4th Year, Large Entity 14 Sep, 2017 US8686026
Payment of Maintenance Fee, 4th Year, Large Entity 14 Sep, 2017 US8691938


Ombitasvir; Paritaprevir; Ritonavir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List